 Equillium Inc NASDAQ: EQ has reported topline data from the Type A group of the Phase 1b EQUALISE study evaluating itolizumab in patients with systemic lupus erythematosus SLE. Data from the study showed that itolizumab was safe and well-tolerated and demonstrated a dose-dependent reduction of cell-surface CD6 expression on effector T cells, a leading indicator of drug activity. 